key: cord-0778319-8m054ud4
authors: Freund, Ophir; Eviatar, Tali; Bornstein, Gil
title: Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review
date: 2022-03-11
journal: Rheumatol Int
DOI: 10.1007/s00296-022-05106-3
sha: 51dabc6663668335a3de58c6673948c0f1bb87b2
doc_id: 778319
cord_uid: 8m054ud4

Adult COVID-19 patients can present with acute muscle and/or cardiac involvement. Our study aims to describe the incidence and characteristics of patients with the co-occurrence of COVID-19 myopathy and inflammatory cardiac disease. We retrospectively reviewed all COVID-19 patients admitted to a large tertiary center to assess the co-occurrence of myopathy and inflammatory cardiac disease. We conducted a literature review of prior relevant case reports. There were three COVID-19 patients with concurrent involvement from our center and five cases in the published literature. Overall, mean age was 57.7 ± 16, four were females (50%) and only two patients (25%) had major relevant comorbidities. Muscle involvement included rhabdomyolysis or myositis and cardiac involvement included myocarditis or pericarditis. Most patients (75%) had no respiratory COVID-19 symptoms. Troponin and creatine phosphokinase levels were higher than twofold of the upper limit of normal for all patients. Steroids were used in the treatment of most patients (75%). All patients had a resolution or improvement of their extra-pulmonary involvement while two (25%) deteriorated due to COVID-19 pneumonia. The incidence for this co-occurrence is 0.07% among hospitalized COVID-19 patients. Patients with these rare COVID-19 simultaneous manifestations have distinct features. They are generally younger, present with extra-pulmonary symptoms and do not have severe respiratory compromise. An underdiagnosis causing treatment delay is possible. Further study is needed.

Severe acute respiratory syndrome caused by the novel coronavirus SARS-CoV-2 is known to cause a wide variety of extra-pulmonary manifestations [1] [2] [3] [4] . These can be either related to a specific organ or mimic a systemic inflammatory disease. Cardiac involvement secondary to COVID-19 occur in over 50% of patients with different presentations, manifestations and complications [2, 5, 6] . Up to 16% of these patients can also be asymptomatic [7, 8] . Skeletal muscle myopathy is an additional extra-pulmonary manifestation of COVID-19, occurring in up to one-third of symptomatic patients and ranging from limited myalgia to myositis or rhabdomyolysis, depending on the authors' definition [9, 10] . While involvement of each system separately is well described among COVID-19 patients, their concurrent appearance is not; only a few cases are reported in the literature. Here we report a case series of patients with concurrent myopathy and inflammatory cardiac disease secondary to active COVID-19 infection and review the literature of such cases.

This is a retrospective case series review in Tel Aviv Sourasky Medical center, a large tertiary center in Israel. Cases were identified from the electronic hospital registry system using the MDClone software [11] . The inclusion process is presented in Fig. 1 . We searched the registry for relevant cases among all patients admitted between March 2020 and August 2021 with proven COVID-19 by oropharyngeal SARS-CoV-2 polymerase chain reaction (PCR) swab. Our Rheumatology INTERNATIONAL * Ophir Freund ophir068@gmail.com 1 Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel 2 Rheumatology Department, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel initial search parameters included adults over the age of 18 with a recorded diagnosis of myopathy or inflammatory cardiac disease during admission (including myocarditis, pericarditis, cardiac tamponade, myositis, myasthenia gravis, and rhabdomyolysis). To avoid the loss of other relevant cases, we also searched for patients that had a peak creatine phosphokinase (CPK) level of at least 1000 U/L (normal 35-145 U/L) with a peak troponin I level of at least 100 ng/L (normal < 50 ng/L). Exclusion criteria were prior diagnosis of any chronic myopathy or cardiac inflammatory disease. Medical records of all cases found using the method above were then reviewed to verify the diagnoses and co-occurrence of myopathy and inflammatory cardiac disease. Only patients diagnosed with new onset myopathy and inflammatory cardiac disease during admission were included in the final series. For this purpose, we reviewed the hospital admission note, previous hospitalizations, clinic visits, and laboratory and imaging results. Diagnoses of myopathy or inflammatory cardiac disease were made based on the presence of relevant symptoms, physical examination findings and either laboratory or imaging findings. We defined these diagnostic criteria for a minimum of a probable confidence diagnosis. A probable diagnosis of Idiopathic Inflammatory Myopathies (IIM) relies mainly on patient complaints, physical examination, and laboratory findings and is considered enough to classify patient as having IIM [12] . The study was approved by the institutional review board (TLV-0546-21).

A case-based search was conducted according to the review strategies recommended in the literature [13] . Using the MEDLINE/PubMed, DOAJ and Scopus databases, we searched the literature for reported cases between January 2020 and October 2021, with the following strategy: ((myositis) OR (myasthenia gravis) OR (rhabdomyolysis) OR (myopathy)) AND ((pericarditis) OR (myocarditis) OR (cardiomyopathy)) AND ((Covid-19) OR (SARS-CoV-2)). 

A total of 4475 patients with COVID-19 diagnosis were admitted in our facility during the specified period and appeared in the MDClone database. Eighty-six cases were found through the hospital registry search (Fig. 1 ). After review, three cases met our inclusion criteria for the case series. Clinical details of these cases are outlined below and summarized in Table 1 .

A 47-year-old female presented with fatigue, myalgia, and fever 5 days after being detected positive for SARS-CoV-2 by oropharyngeal PCR swab. Her medical history included past invasive ductal carcinoma of her left breast (2011) and fibromyalgia. Vital signs included tachycardia of 120 beats per minute, blood pressure 103/87 mmHg with normal O2 saturation at room air and no fever. Bilateral lower limb tenderness on palpation was noted on physical examination. Initial troponin level was 396 ng/L. After several hours, a sudden deterioration occurred with O2 de-saturation of 83% at room air, hypotension of 77/40 mmHg and metabolic scan showed bilateral lung ground-glass opacities consistent with COVID-19, mild pericardial thickening consistent with pericarditis, and edema of the proximal lower limb musculature consistent with myositis ( Fig. 3) . Treatment with Remdesivir, dexamethasone and tocilizumab were given in accepted dosages per-institutional protocol for severe COVID-19 [14] [15] [16] . General improvement was noted on day 5 with decreased myalgia, increase of iliopsoas strength to 4\5 and resolution of upper limb weakness.

A 41-year-old female presented with bilateral lower limb weakness, cough, and fever for 2 days. She was detected positive for SARS-CoV-2 by oropharyngeal PCR swab upon arrival. Her medical history includes chronic kidney disease secondary to polycystic kidney disease with a baseline creatinine of 6 mg/dL. Vital signs were within normal range, bilateral proximal lower limb weakness was noted upon medical examination. Initial laboratory results showed a creatinine of 18.5 mg/dL without any electrolyte abnormalities, venous blood gases with pH of 7.14 and bicarbonate of Dexamethasone, Remdesivir, Tocilizumab Dexamethasone, Casirivimab and Imedevimab Dexamethasone 5.7 mmol/L. An urgent dialysis was performed with resolution of acidosis. Treatment with dexamethasone was initiated and a single dose of monoclonal anti-SARS-CoV-2 antibodies (Casirivimab and Imedevimab antibodies) was given due to low anti-SARS-CoV-2 spike IgG levels [17] . The patient completed second dialysis session 12 h after admission to the COVID-19 department. First CPK level, taken on day 2, was 1150 U/L with improvement of lower limbs weakness on day 3. Upon arrival to the COVID-19 department, the patient complained of dyspnea which appeared with minimal effort combined with generalized fatigue. First troponin level taken on day 2 was 399 ng/L. TTE showed severe global LV systolic dysfunction with ejection fraction (EF) of 30%, which was a new finding in comparison with a TEE performed in December 2019. The patient continued dialysis with improvement of symptoms and was transferred to a non-COVID-19 internal medicine department after recovery from COVID-19. Two weeks later, coronary angiography showed a non-significant coronary artery disease and a follow-up TTE showed improvement of global systolic dysfunction with an EF of 40%.

A 91-year-old male presented with 2 days of extreme bilateral lower limb weakness ("could not stand") and shortness of breath. He was detected positive for SARS-CoV-2 by oropharyngeal PCR swab upon arrival. His medical history included a mild cognitive impairment, paroxysmal atrial fibrillation, hypertension, dyslipidemia, chronic kidney disease with baseline creatinine of 1.5 mg/ dL and prior smoking (more than 20 years ago) with 40 pack years. Upon admission abnormal vital signs included fever of 39.2 degrees Celsius and oxygen saturation of 86% at room air elevated to 95% while using oxygen nasal cannula. Blood pressure and heart rate were within normal range. Physical examination was noticeable for bilateral proximal lower limb weakness without signs of dyspnea or tachypnea. Chest radiograph (CXR) showed an enlarged heart silhouette (Fig. 4) . Bedside TTE showed moderate pericardial effusion. Initial lab results included elevated troponin level of 121 ng/L and a CPK level of 5011 U/L, both peaked the following day at 1057 ng/dL and 8575 U/L, respectively. Treatment with Dexamethasone was initiated. Two days after admission, lower limb weakness has improved, and the patient was able to walk with assistance. However, the following day a respiratory deterioration occurred and was attributed to worsening of COVID-19 pneumonia. Oxygen desaturation continued to worsen, and the patient required high flow nasal cannula. Three days later the patient died due to respiratory failure.

We identified 26 articles with a case description, and after reviewing, only 5 were included in our case series using the above inclusion criteria. We excluded eight cases of patients with only myopathy or inflammatory cardiac disease, five cases with a known myopathy or inflammatory cardiac disease, four cases of patients without COVID-19, three cases describing the effect of COVID-19 vaccine, and one case of a patient under 18 years. The characteristics of the included cases are summarized in Table 2 [18] [19] [20] [21] [22] . Median age was 50 (39-78) years and only one patient had a history of prior cardiac disease. The presenting symptom in all patients was related to one of the extra-pulmonary systems and 80% had no COVID-19-related respiratory symptoms. Steroids were part of the treatment regimen of three patients, colchicine for two patients and hydroxychloroquine for one.

In this article, we present the first case series of COVID-19 patients with concurrent myopathy and inflammatory cardiac disease. Our study sample included two young patients, in accordance with the relatively young age of the patients from the reviewed cases (overall median 49, range 39-91). Previous reports showed a wide age variety of COVID-19 patients with any of these manifestations [2, 3] . Overall, only one patient (12.5%) had multiple cardiovascular or neuromuscular comorbidities [18] . In addition, only two patients (25%) did not recover and suffered from further deterioration. These findings are in contrary to the higher rates of cardiovascular comorbidities and worse outcomes as seen in previous studies among COVID-19 patients with cardiac complications [1, 5] . A reasonable explanation might be the exclusion of patients from our study with any vascular complications such as myocardial infraction or stroke or any complication secondary to sepsis or shock. At least one of the extra-pulmonary manifestations occurred for all patients early during the course of the disease, in line with previous findings on COVID-19 related myositis or myocarditis [2] . COVID19 related myopathy and cardiac complications are known to have a strong inflammatory component [10, 23, 24] . Concomitant involvement can also occur in inflammatory myopathies or as a side effect of drugs such as checkpoint inhibitors which further highlight the possible inflammatory (as opposed to infectious) mechanism for this association [25, 26] . In our case series considered together with cases from the literature review and other, most patients did not have a major respiratory complication and only two had critical COVID-19 pneumonia [4, 22] . There might be a different mechanism leading to the involvement of each system in COVID-19, inflammatory or else, which can explain this finding. Other infectious agents, including viruses, bacteria and parasites, are known to trigger autoimmunity, which may also play a key role in the development of extra-pulmonary COVID-19 disease [27] . Molecular mimicry is a possible mechanism causing autoimmunity in COVID-19 disease, with known shared epitopes between human and SARS-COV-2 proteins [2, 23, 28] . COVID-19 has also been associated with activation of the innate immunity, which may transform into autoimmunity [27] . Another proposed mechanism for autoimmunity is the persistence of SARS-COV-2 in the host long before it is detected, leading to prolong innate immunity activation [3] .

Myopathy and inflammatory cardiac disease in covid-19 are common, while their concurrent involvement is rare, and its incidence is yet to be described. Romero-Sánchez et al. demonstrated that among hospitalized patients with COVID-19, muscle damage was the most prominent neuromuscular manifestation, with myopathy and rhabdomyolysis at incidence of 3.1% and 1.1%, respectively [30] . Another study that summarized COVID-19 patients who undergone echocardiography found myocarditis and cardiac tamponade in 3% and 1% of the patients, respectively [31] . Based on our analysis among all COVID-19 patients in our medical center, the incidence of patients with concurrent involvement was 0.07%, although there may have been underdiagnosis of such cases, effecting early treatment and outcomes.

Cases with simultaneous muscle and cardiac involvement might present a diagnostic challenge. Myositis can be overlooked unless its diagnosis is supported by laboratory or directed imaging and functional tests. In comparison with the reviewed cases and previous studies, patients in our case series had atypical cardiac complaints, further delaying their diagnosis [24, 32] . Troponin and CPK levels were high among all patients and TTE was effective in demonstrating the cardiac pathology, all of which seem to be reliable and basic diagnostic tools that are available in most clinical settings. While further investigations with modalities such as magnetic resonance imaging (MRI) are needed to establish a diagnosis, they are usually not available for most COVID-19 patients due to logistical or resources issues.

Therapeutic dilemmas may appear as well. Non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are considered first-line treatments for acute pericarditis [33] while glucocorticoids are selected as second-line treatment (due to a higher recurrence rate during steroids tapering down). However, no specific treatment was proven for myocarditis. In addition, a treatment which is suitable for one system might have an adverse effect on the other. NSAIDS usage for pericardial involvement in patients otherwise healthy might worsen kidney function if a concurrent rhabdomyolysis exists. In our report, dexamethasone was the most frequent drug of choice, as it was used for all cases in our series and in three others from the review. Steroids are widely used in severe COVID-19 and are accepted as a first-line therapy in cases of myositis attributed to other etiologies [15, 34] . It seems reasonable to use dexamethasone for such cases, as already described for COVID-19-related myocarditis [35] . No evidence of adverse effects was noted for any of the treatments probably due to short-term use and immediate quit from treatment. Our report has several limitations. First, our initial inclusion criteria and retrospective nature of this study may fail to recognize other patients with milder signs and symptoms, or without a declared diagnosis, but we have tried to overcome this by adding the laboratory criteria. Second, diagnosis of any extrapulmonary involvement was based mostly on clinical and laboratory findings without histopathologic, electromyographic or MRI confirmation. To ascertain the relationship between COVID-19 disease and the time onset of the inflammatory disease, we reviewed medical records prior to admission. Still, this relationship may be interrupted by a sub-clinical disease or unreported symptoms that were present before COVID-19 disease onset. The follow-up time is short and restricted to the hospitalization period which renders our study unable to assess for recurrence of symptoms and signs and late prognosis. We also acknowledge that our study design and the small sample size was not suitable to assess the efficacy of the different treatments.

In conclusion, COVID-19 can manifest a myriad of inflammatory complications, amongst myopathy and inflammatory cardiac disease; their concurrent involvement seems to be rare yet probably underdiagnosed. Our study raises awareness to the unique characteristics of these cases and may shed light on the shared pathophysiology of these COVID-19 complications. Larger studies and case series are needed to define the best treatment strategy for this myopathic complication and its long-term prognosis.

Funding This study was not funded by any source.

Conflict of interest Ophir Freund, Tali Eviatar, and Gil Bornstein declare that they have no conflict of interest.

The study was approved by the Sourasky medical center institutional review board (TLV-0546-21). The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. This is a retrospective study and details that might disclose the identity of the subjects under study was omitted as possible.

Extrapulmonary manifestations of COVID-19

Systemic and organ-specific immune-related manifestations of COVID-19

COVID-19 and the clinical course of rheumatic manifestations

Reactive arthritis after COVID-19: a case-based review

Cardiac involvement in COVID-19 patients: risk factors, predictors, and complications : a review

Cardiovascular complications in COVID-19

Cardiac involvement in MRI in young population after COVID-19: a single tertiary center experience

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Rhabdomyolysis as the main manifestation of coronavirus disease 2019

COVID-19 and Myositis: What We Know So Far

MdClone -Dynamic Data Exploration

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups HHS public access

Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dexamethasone in hospitalized patients with Covid-19

Remdesivir for the treatment of Covid-19-final report

Subcutaneous REGEN-COV antibody combination to prevent Covid-19

Myopericarditis and myositis in a patient with COVID-19: a case report

Myopericarditis, rhabdomyolysis, and acute hepatic injury: sole expression of a SARS-CoV-2 infection

An atypical case of COVID-19 induced pancytopenia rhabdomyolysis and myocarditis

Multimodal findings of COVID-19-related rhabdomyolysis complicated with pericarditis mimicking fulminant myocarditis

SARS-CoV-2 infection with associated rhabdomyolysis and probable myocarditis

Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment

Abrol S (2020) Cardiac tamponade in COVID-19 patients: Management and outcomes

Fulminant myocarditis with combination immune checkpoint blockade

Cardiac tamponade as a manifestation of severe dermatomyositis

Infection and autoimmune disease

Molecular mimicry may explain multi-organ damage in COVID-19

COVID 19: a clue from innate immunity

Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry

Global evaluation of echocardiography in patients with COVID-19

SARS-CoV-2: a potential novel etiology of fulminant myocarditis

ESC Guidelines for the diagnosis and management of pericardial diseases

Update on the pharmacological treatment of adult myositis

Corticosteroid therapy in management of myocarditis associated with COVID-19; a systematic review of current evidence